Guest guest Posted December 24, 2010 Report Posted December 24, 2010 's right that insurance isn't likely to cover it, unless they're unfamiliar with the vaccine and assume it's a routine vaccination. But it's not cheap, so they're likely to question it. Even for the boys 9-26 for whom it's indicated, the ACIP still won't put it on the list of recommended vaccinations--meaning that public payers (and therefore private payers) won't cover it. They did carve out an " optional " recommendation for MSM, but how many parents are going to insist that their sons are gay to their provider so they can get the vaccine, and then fight with the insurance companies for coverage? Regarding those over 27, the ACTG is planning a trial in HIV+ MSMs over 27 to measure its effect--which will be useful for the rest of us. Stay tuned, and sign up with an ACTG site near you..... Jeff Re: NATAP: FDA Approves GARDASIL for Anal Cancer Posted by: " Vergel " Vergel@... nelsonvergel Thu Dec 23, 2010 8:51 pm (PST) I doubt that you can get your insurance to pay since you are older than theage range on the label. Besides, Merck keeps telling us that it will notwork for most of us since we have already been exposed to the most cancer producing genotypes. Unfortunately, HPV genotype tests are only availablefor research purposes (I wish we could have access to it)A study showed that the HPV vaccine may work for some gay menhttp://www.aidsmeds.com/articles/hpv_vaccine_men_1667_18835.shtml I think the total cost for the 3 shots is close to $400. You can get it atyour doctor's office. I would love to have access to genotype testing tofind out if I really would be wasting my money if I were to decide to get the shots.Jeff may be able to expand more on this.On Thu, Dec 23, 2010 at 10:15 PM, Jim98122x <jim98122x@...> wrote: >>> Does anyone know what this means for those of us who are *(**WAY**)*over> 26, as relates to having insurance pay for it? I assume that would be> considered " *off label* " --- Would most insurances pay for it, if it hasn't > yet technically been demonstrated to be useful for people over the age of> 26? My insurance pays for most vaccinations without a copay, but I expect> this might be a reason why they'd not pay for it. Anyone with any insight > about this sort of thing?>>>> > >> >> > > Subject: NATAP: FDA Approves GARDASIL for Anal Cancer> > >> > >> > >> > > Dec. 22, 2010> > > US FDA Approves New Indication for Merck's HPV Vaccine, GARDASIL® > > > US FDA Approves New Indication for Merck's HPV Vaccine, GARDASIL®> > >> > > GARDASIL now Approved for Prevention of Anal Cancer and AIN> > >> > > WHITEHOUSE STATION, N.J., Dec. 22, 2010 - Merck, known as MSD outside > the United States and Canada, announced today that the U.S. Food and Drug> Administration (FDA) has approved GARDASIL® [Human Papillomavirus> Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the > prevention of anal cancer caused by human papillomavirus (HPV) types 16 and> 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1,> 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, > 11, 16 and 18, in males and females 9 through 26 years of age.> > >> > > " We are pleased that with this new indication for GARDASIL against> HPV-related anal cancer and disease, both males and females can be protected > against cancer, which further reinforces the importance of vaccinating both> genders, " said M. Haupt, M.D., MPH, executive director, Merck> Research Laboratories. " GARDASIL is the only HPV vaccine available for use > in both males and females, and the only one indicated to help prevent> cervical, vaginal, vulvar and anal cancers and pre-cancers, as well as> genital warts, caused by certain types of HPV. " > > > > > > In the United States, an estimated 75 to 80 percent of males and> females will be infected with HPV in their lifetime. For most, HPV will> clear on its own. However, for those who don't clear certain types, HPV can > cause cervical, vaginal and vulvar cancers in women and anal cancer and> genital warts in men and women. There is no way to predict who will or won't> clear the virus.> > >> > > GARDASIL helps protect against the four types of HPV, specifically > types 6, 11, 16, and 18, that cause the most disease. It is estimated that> HPV types 16 and 18 account for approximately 80 percent of anal cancers, 75> percent of cervical cancers, 70 percent of vaginal cancers and 40 to 50 > percent of vulvar cancers. HPV types 6 and 11 cause approximately 90 percent> of all genital warts cases.> > >> > > Anal cancer affects both men and women, with approximately 60 percent > of cases occurring in women. According to the American Cancer Society, it is> estimated that approximately 2,000 men and more than 3,000 women will have> been diagnosed with anal cancer in 2010. There is no standardized screening > recommended for the general population for anal cancer and many people are> diagnosed when the disease is more advanced.> > >> > > GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) > Vaccine, Recombinant] was approved in the United States in 2006 and is also> indicated for use in girls and young women 9 through 26 years of age for the> prevention of cervical, vulvar and vaginal cancers caused by HPV types 16 > and 18; genital warts (condylomata acuminata) caused by HPV types 6 and 11;> and precancerous or dysplastic lesions caused by HPV types 6, 11, 16 and 18.> GARDASIL is also approved in the U.S. for use in boys and men ages 9 through > 26 years of age for the prevention of genital warts caused by HPV types 6> and 11.> > >> > > Important information about GARDASIL> > > GARDASIL does not eliminate the necessity for women to continue to > undergo recommended cervical cancer screening.> > >> > > Recipients of GARDASIL should not discontinue anal cancer screening if> it has been recommended by a health care provider. > > >> > > GARDASIL has not been demonstrated to provide protection against> diseases from vaccine and non-vaccine HPV types to which a person has> previously been exposed through sexual activity. > > >> > > GARDASIL is not intended to be used for treatment of active external> genital lesions; cervical, vulvar, vaginal, and anal cancers; cervical> intraepithelial neoplasia, vulvar intraepithelial neoplasia, vaginal > intraepithelial neoplasia, or anal intraepithelial neoplasia.> > >> > > GARDASIL has not been demonstrated to protect against disease due to> HPV types not contained in the vaccine. > > >> > > Not all vulvar, vaginal, and anal cancers are caused by HPV, and> GARDASIL protects only against those vulvar, vaginal, and anal cancers> caused by HPV 16 and 18.> > > > > > Select safety information> > > GARDASIL is contraindicated in individuals with hypersensitivity,> including severe allergic reactions to yeast, or after a previous dose of> GARDASIL. > > >> > > Because vaccinees may develop syncope, sometimes resulting in falling> with injury, observation for 15 minutes after administration is recommended.> Syncope, sometimes associated with tonic-clonic movements and other > seizure-like activity, has been reported following vaccination with> GARDASIL. When syncope is associated with tonic-clonic movements, the> activity is usually transient and typically responds to restoring cerebral > perfusion.> > >> > > GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18)> Vaccine, Recombinant] is not recommended for use in pregnant women.> > >> > > The most common adverse reaction was headache. Common adverse reactions > that were observed among recipients of GARDASIL at a frequency of at least> 1.0 percent and greater than placebo were: fever, nausea, dizziness; and> injection-site pain, swelling, erythema, pruritus and bruising. > > >> > > Dosage and administration for GARDASIL> > > GARDASIL is a ready-to-use, three-dose, intramuscular vaccine. GARDASIL> should be administered in three separate intramuscular injections in the > deltoid region of the upper arm or in the higher anterolateral area of the> thigh. The following dosage schedule is recommended: First dose at elected> date, second dose two months after the first dose and the third dose six > months after the first dose.> > >> > > GARDASIL is approved in 121 countries> > > GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18)> Vaccine, Recombinant] (sold in some countries as SILGARD®) has been approved > in 121 countries, and additional applications are currently under review> with regulatory agencies in many more countries around the world. Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.